About Christopher Murphy
Form D filings for MCAL Therapeutics from 2020 to 2024 list Christopher Murphy as director.
Christopher Murphy first appears on SEC filings in 2020.
Experience
This experience comes from SEC filings. The years are when the filings name Christopher Murphy in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Christopher Murphy works with at each company, as listed on that company's latest Form D.
MCAL Therapeutics Inc. · Form D, Mar 27, 2024
TG
Tom Gadek
Chief Executive Officer and director
CN
Charles O'Neill
Director
DA
Dan Albert
Director
TM
Tom Mather
Director